: Now after reading the original paper (), I notice that the authors themselves note a possible therapeutic strategy. RBBP4 works at least in part through the PKA-CREB1-CPB pathway.  The author have previously shown () that dopamine D1/D5 agonists such as 6-Br-APB and SKF-38,393 that are positively coupled to adenylyl cyclase and the cAMP phosphodieserase inhibitor rolipram reduced meomory defects in aged mice.